Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on December 12, 2017. The report covers a specific corporate event occurring on the same date. Note: The metadata provided lists "Cardiff Oncology, Inc.", but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific operational event and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the commercial availability of the Company's proprietary NextCollect urine collection and DNA preservation kit. As of December 12, 2017, this product is available for research use only to clinical research laboratories and pharmaceutical customers.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, management commentary on future performance, or a discussion of risks and contingencies. The report is limited to the announcement of the product launch.
Key Facts for Investor Verification
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the NextCollect kit is currently restricted to "research use only" and not yet approved for clinical diagnostic use.
- Review the attached press release (Exhibit 99.1) for specific details on the product's capabilities and target market.